Advertisement

Advertisement

STOK Stock Latest News

De-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen

RatingsDe-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen

Advancing Zorevunersen in Dravet Syndrome: Late‑Stage Trial Clarity and Regulatory Momentum Support Buy Rating on Stoke Therapeutics

PremiumRatings

Advancing Zorevunersen in Dravet Syndrome: Late‑Stage Trial Clarity and Regulatory Momentum Support Buy Rating on Stoke Therapeutics

16d ago

Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight

PremiumCompany Announcements

Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight

23d ago

Stoke Therapeutics price target raised to $60 from $36 at Canaccord

PremiumThe Fly

Stoke Therapeutics price target raised to $60 from $36 at Canaccord

1M ago

Stoke Therapeutics files automatic mixed securities shelf

PremiumThe Fly

Stoke Therapeutics files automatic mixed securities shelf

1M ago

Stoke Therapeutics price target raised to $38 from $36 at Wedbush

PremiumThe FlyStoke Therapeutics price target raised to $38 from $36 at Wedbush

1M ago

Stoke Therapeutics price target raised to $38 from $36 at Wedbush

The Fly

Stoke Therapeutics price target raised to $38 from $36 at Wedbush

1M ago

STOK Earnings this Week: How Will it Perform?

Pre-Earnings

STOK Earnings this Week: How Will it Perform?

2M ago

Stoke Therapeutics, Biogen publish data from zorevunersen studies in NEJM

PremiumThe Fly

Stoke Therapeutics, Biogen publish data from zorevunersen studies in NEJM

2M ago

Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP

PremiumThe Fly

Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP

2M ago

Stoke Therapeutics Awards Discretionary Bonus to CEO Smith

PremiumCompany Announcements

Stoke Therapeutics Awards Discretionary Bonus to CEO Smith

2M ago

Stoke Therapeutics initiated with an Outperform at Wolfe Research

PremiumThe Fly

Stoke Therapeutics initiated with an Outperform at Wolfe Research

2M ago

Stoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald

PremiumThe FlyStoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald

2M ago

Stoke Therapeutics initiated with a Buy at Guggenheim

The Fly

Stoke Therapeutics initiated with a Buy at Guggenheim

3M ago

Stoke Therapeutics Expands with New Long-Term Waltham Headquarters

Company Announcements

Stoke Therapeutics Expands with New Long-Term Waltham Headquarters

3M ago

Stoke Therapeutics price target raised to $36 from $32 at Wedbush

PremiumThe Fly

Stoke Therapeutics price target raised to $36 from $32 at Wedbush

4M ago

Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline

PremiumCompany Announcements

Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline

4M ago

Stoke Therapeutics updates timeline for Phase 3 EMPEROR study

PremiumThe Fly

Stoke Therapeutics updates timeline for Phase 3 EMPEROR study

4M ago

Stoke Therapeutics price target raised to $36 from $28 at Canaccord

PremiumThe Fly

Stoke Therapeutics price target raised to $36 from $28 at Canaccord

4M ago

Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright

PremiumThe FlyStoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright

5M ago

Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting

Company Announcements

Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting

5M ago

Biogen, Stoke Therapeutics announce data presentations for zorevunersen

The Fly

Biogen, Stoke Therapeutics announce data presentations for zorevunersen

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >